Want to see HK:1521 full AI Analyst Report?
Top Page
Frontage Holdings Corp.
(1521)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$1.50
▲(45.63% Upside)
Action:Reiterated
Date:10/22/26
The score is supported most by strong technical momentum (price above all key moving averages with positive MACD). Financial performance is adequate but held back by margin compression, low returns on equity, and volatile free cash flow. Valuation also constrains the score due to a high P/E and no dividend yield.
Positive Factors
Long-term revenue expansion
Revenue expanded strongly from 2020 to 2025, with a sharp rebound in 2025 after a slight 2024 decline. This demonstrates the company’s ability to grow its property-related business over time, although recent growth has been uneven.
Negative Factors
Structural margin compression
The sustained decline in gross margin shows that revenue growth has not translated into comparable profitability. With margins well below earlier levels, the company may have less earnings cushion and reduced capacity to absorb operating or property-market pressures.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term revenue expansion
Revenue expanded strongly from 2020 to 2025, with a sharp rebound in 2025 after a slight 2024 decline. This demonstrates the company’s ability to grow its property-related business over time, although recent growth has been uneven.
Read all positive factors
Frontage Holdings Corp. (1521) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.04B
Dividend YieldN/A
Average Volume (3M)132.27K
Price to Earnings (P/E)36.5
Beta (1Y)0.46
Revenue Growth10.32%
EPS Growth178.23%
CountryHK
Employees1,800
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,042,075,000
10 Day Avg. Volume285,400
30 Day Avg. Volume132,266
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.75
Price to Sales (P/S)1.01
P/FCF Ratio8.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$287.62M
Frontage Holdings Corp. Business Overview & Revenue Model
Company Description
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequi...
How the Company Makes Money
Frontage Holdings Corp. makes money primarily through revenue earned from real estate-related activities. Key revenue streams typically include proceeds and margins from selling properties (including trading/flip-type transactions where the compan...
Frontage Holdings Corp. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.95M | 256.69M | 254.91M | 259.86M | 250.36M | 184.44M |
| Gross Profit | 71.69M | 69.20M | 69.81M | 78.39M | 89.19M | 66.70M |
| EBITDA | 57.85M | 50.95M | 45.55M | 55.78M | 63.42M | 49.21M |
| Net Income | 10.60M | 6.79M | 791.00K | 10.81M | 25.73M | 18.43M |
Balance Sheet | ||||||
| Total Assets | 580.39M | 540.95M | 553.59M | 571.87M | 550.59M | 475.84M |
| Cash, Cash Equivalents and Short-Term Investments | 36.82M | 39.14M | 44.09M | 54.60M | 90.52M | 148.71M |
| Total Debt | 140.87M | 127.60M | 154.37M | 145.10M | 118.19M | 57.85M |
| Total Liabilities | 222.21M | 191.02M | 219.32M | 226.72M | 214.75M | 152.76M |
| Stockholders Equity | 354.84M | 346.74M | 333.00M | 342.50M | 333.08M | 319.84M |
Cash Flow | ||||||
| Free Cash Flow | 36.60M | 32.27M | 14.75M | 18.59M | 14.78M | -5.83M |
| Operating Cash Flow | 50.82M | 43.93M | 40.64M | 39.74M | 62.44M | 44.55M |
| Investing Cash Flow | -50.27M | -13.85M | -41.48M | -87.63M | -147.91M | -107.44M |
| Financing Cash Flow | -396.00K | -37.36M | -10.22M | 12.91M | 30.66M | -5.54M |
Frontage Holdings Corp. Technical Analysis
Positive
1.03
Price Trends
1.19
Positive
1.12
Positive
1.07
Positive
Market Momentum
0.03
Negative
76.51
Negative
83.53
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1521, the sentiment is Positive. The current price of 1.03 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.19, and below the 200-day MA of 1.07, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 76.51 is Negative, neither overbought nor oversold. The STOCH value of 83.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1521.
Frontage Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$206.04B | 34.71 | 10.51% | ― | 21.93% | 21.94% | |
68 Neutral | HK$63.92B | 52.50 | 5.86% | 1.12% | 16.62% | >-0.01% | |
64 Neutral | HK$75.94B | -14.65 | -16.23% | 0.35% | 53.48% | -120.02% | |
63 Neutral | HK$3.04B | 36.52 | 3.02% | ― | 10.32% | 178.23% | |
61 Neutral | HK$20.21B | 45.50 | 15.94% | ― | 48.04% | 166.72% | |
59 Neutral | HK$76.49B | 39.90 | 10.96% | 0.84% | 20.39% | 26.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1521
Frontage Holdings Corp.
1.49
0.37
33.04%
HK:1548
Genscript Biotech
32.88
17.06
107.84%
HK:2269
Wuxi Biologics (Cayman)
45.26
9.76
27.49%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
26.06
2.37
9.99%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
41.22
17.82
76.15%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
119.80
32.16
36.70%
Frontage Holdings Corp. Corporate Events
Frontage Holdings Requests Trading Halt Ahead of Takeover-Related Announcement
Oct 22, 2026
Frontage Holdings has requested a trading halt in its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on October 22, 2026. The suspension precedes the release of an announcement under Hong Kong’s Code on Takeovers and Merger...
Frontage Holdings Delivers Strong First-Half 2026 Profit Growth on Higher Revenue
Aug 28, 2026
Frontage Holdings Corporation reported solid growth for the six months ended June 30, 2026, with revenue rising 17.1% year-on-year to US$148.2 million and EBITDA increasing 17.4% while maintaining a stable EBITDA margin of 21.4%. Despite a slight ...
Frontage Holdings Schedules Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
Frontage Holdings Corporation has scheduled a board meeting for August 28, 2026 to review and approve the interim results for the six months ended June 30, 2026. The board will also consider whether to declare an interim dividend, a decision that ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.